My Cart Find A Store

Drug

Trastuzumab-Hyaluronidase-Oysk

Pronounced

"tras-TOOZ-ue-mab"

Uses

Trastuzumab is used to treat breast cancer. Trastuzumab belongs to a class of medications known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. This product also contains hyaluronidase, which helps your body absorb trastuzumab given by injection under the skin.

This monograph is about the following trastuzumab products: trastuzumab (subcutaneous) and trastuzumab-hyaluronidase-oysk. These products are not the same as other trastuzumab products, including trastuzumab emtansine, or trastuzumab given by injection into a vein, and should not be used in place of each other.

Warning

Trastuzumab may cause serious heart problems, including heart failure. The risk of heart problems is increased if you also use an anthracycline (such as doxorubicin). Your doctor may stop treatment with this medication if heart problems occur. Tell your doctor right away if you have any symptoms of heart failure (such as shortness of breath, swelling ankles/feet, unusual tiredness, unusual/sudden weight gain).

Serious (possibly fatal) breathing problems may happen with your injection, usually during or within 24 hours of the dose. Get medical help right away if you have coughing or trouble breathing.

Trastuzumab can cause serious (possibly fatal) harm to an unborn baby if used during pregnancy. Discuss reliable forms of birth control with your doctor.

How to Use This Medication

This medication is given by slow injection (over 2 to 5 minutes) under the skin by a health care professional. It is given as directed by your doctor, usually once every 3 weeks. The injection is given in the thigh and the injection site and side are changed each time to lessen injury under the skin. The dosage is based on your medical condition and response to treatment.

Use this medication regularly to get the most benefit from it. To help you remember, mark your calendar with a reminder.

Serious reactions, including an allergic reaction, may happen with your injection, usually within 24 hours after your dose. Your doctor may prescribe other medications (such as acetaminophen, diphenhydramine) before each dose to help prevent these side effects. Get medical help right away if you have any symptoms of serious reactions such as fever, chills, flushing, headache, nausea/vomiting, coughing, chest pain, trouble breathing, itching/swelling (especially of the face/tongue/throat), dizziness, weakness, or feeling faint.

Copyright © 2025 TraceGains, Inc. All rights reserved.

RxAnswers™ is a copyrighted combined product from TraceGains and First DataBank, Inc.

Drug information is selected from data included with permission and copyrighted by First DataBank, Inc. This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional. Always seek the advice of your healthcare professional if you have any questions about this product or your medical condition. This information is not intended as individual medical advice and does not substitute for the knowledge and judgment of your healthcare professional. This information does not contain any assurances that this product is safe, effective or appropriate for you.

This information is intended only for residents of the United States. Products sold under the same brand names in other countries may contain different ingredients.

Learn more about First DataBank

There are some limitations on the information provided in “Nutrient Interactions.” Do NOT rely solely on the information in this article. Please read the disclaimer

Learn more about TraceGains, the company.

TraceGains and/or its suppliers make no warranties or representations as to the accuracy or completeness of this content herein or that of any organization referred or linked to within this content and will not be liable for any damages arising out of your access to or use of any information found herein or that of any organization referred to within this content.

Information expires December 2025.